ZA932397B - Pyrimidine derivatives and processes for the preparation thereof. - Google Patents

Pyrimidine derivatives and processes for the preparation thereof.

Info

Publication number
ZA932397B
ZA932397B ZA932397A ZA932397A ZA932397B ZA 932397 B ZA932397 B ZA 932397B ZA 932397 A ZA932397 A ZA 932397A ZA 932397 A ZA932397 A ZA 932397A ZA 932397 B ZA932397 B ZA 932397B
Authority
ZA
South Africa
Prior art keywords
stands
free
substituted
amino
lower alkyl
Prior art date
Application number
ZA932397A
Inventor
Juerg Zimmermann
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4202064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA932397(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA932397B publication Critical patent/ZA932397B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

There are described N-phenyl-2-pyrimidinamine derivatives of the formula I <IMAGE> in which R1 denotes 4-pyrazinyl, 1-methyl-1H-pyrrolyl, phenyl substituted by amino or amino-lower alkyl, in which the amino group is in each case free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded to a five-membered ring carbon atom, or pyridyl which is bonded to a ring carbon atom, unsubstituted or substituted by lower alkyl and unsubstituted or substituted by oxygen on the nitrogen, R2 and R3 independently of one another each denote hydrogen or lower alkyl, one or two of the radicals R4, R5, R6, R7 and R8 each denote nitro, fluorine-substituted lower alkoxy or a radical of the formula II -N(R9)-C(=X)-Y)n-R10 (II> in which R9 stands for hydrogen or lower alkyl, X stands for oxo, thio, imino, N-lower alkylimino, hydroximino or O-lower alkylhydroxyimino, Y stands for oxygen or the group NH, n stands for 0 or 1 and R10 stands for an aliphatic radical having at least 5 C atoms or for an aromatic, aromatic-aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or heterocyclic-aliphatic radical, and the remainder of the radicals R4, R5, R6, R7 and R8 independently of one another each denote hydrogen, lower alkyl which is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or morpholinyl, lower alkanoyl, trifluoromethyl, free, etherified or esterified hydroxyl, free, alkylated or acylated amino or free or esterified carboxyl. These compounds can be used e.g. for the therapy of cancers.
ZA932397A 1992-04-03 1993-04-02 Pyrimidine derivatives and processes for the preparation thereof. ZA932397B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH108392 1992-04-03

Publications (1)

Publication Number Publication Date
ZA932397B true ZA932397B (en) 1993-10-04

Family

ID=4202064

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932397A ZA932397B (en) 1992-04-03 1993-04-02 Pyrimidine derivatives and processes for the preparation thereof.

Country Status (29)

Country Link
EP (1) EP0564409B1 (en)
JP (1) JP2706682B2 (en)
KR (1) KR100261366B1 (en)
CN (1) CN1043531C (en)
AT (1) ATE188964T1 (en)
AU (1) AU666709B2 (en)
BR (1) BR1100739A (en)
CA (1) CA2093203C (en)
CY (2) CY2229B1 (en)
CZ (1) CZ283944B6 (en)
DE (2) DE59309931D1 (en)
DK (1) DK0564409T3 (en)
ES (1) ES2142857T3 (en)
FI (1) FI109534B (en)
GR (1) GR3032927T3 (en)
HU (2) HU227080B1 (en)
IL (1) IL105264A (en)
LU (1) LU90908I2 (en)
MX (1) MX9301929A (en)
NL (1) NL300086I2 (en)
NO (2) NO302473B1 (en)
NZ (1) NZ247299A (en)
PT (1) PT564409E (en)
RU (1) RU2125992C1 (en)
SA (1) SA93140441B1 (en)
SG (1) SG43859A1 (en)
SK (1) SK280620B6 (en)
TW (1) TW225528B (en)
ZA (1) ZA932397B (en)

Families Citing this family (350)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
US6171786B1 (en) 1992-09-17 2001-01-09 Board Of Trustees Of University Of Illinois Methods for preventing multidrug resistance in cancer cells
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
AU693475B2 (en) * 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
CZ290681B6 (en) * 1993-10-01 2002-09-11 Novartis Ag N-phenyl-2-pyrimidineamine derivatives, process of their preparation pharmaceutical preparations in which the derivatives are comprised as well as their use
JP3588116B2 (en) * 1993-10-01 2004-11-10 ノバルティス アクチェンゲゼルシャフト Pharmacologically active pyrimidineamine derivatives and process for their production
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
JP3806144B2 (en) * 1993-12-22 2006-08-09 セルテック セラピューティックス リミテッド Trisubstituted phenyl derivatives, their preparation and their use as phosphodiesterase (type IV) inhibitors
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5756527A (en) * 1995-06-07 1998-05-26 Ontogen Corporation Imidazole derivatives useful as modulators of multi drug resistances
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
EP0812830A1 (en) * 1996-06-14 1997-12-17 Ontogen Corporation Modulators of multi-drug resistances
EP0812829A1 (en) * 1996-06-14 1997-12-17 Ontogen Corporation Substituted imidazoles as modulators of multi-drug resistance
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (en) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
MXPA02002559A (en) 1999-09-10 2002-07-30 Merck & Co Inc Tyrosine kinase inhibitors.
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
EP1257546A1 (en) * 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP1315715B1 (en) 2000-08-18 2008-07-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
SK287335B6 (en) * 2000-10-27 2010-07-07 Novartis Ag Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin- 3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for the preparation of pharmaceutical compositions for the treatment of gastrointestinal stromal tumours
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP3406249A1 (en) 2001-02-19 2018-11-28 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor
SE0100569D0 (en) * 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
CA2439268C (en) 2001-02-27 2010-01-19 Novartis Ag Combination comprising a signal transduction inhibitor and an epothilone derivative
HUP0400038A3 (en) 2001-05-16 2007-05-29 Novartis Ag Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
US20030176443A1 (en) * 2001-05-16 2003-09-18 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
EP2322627A3 (en) 2001-06-14 2011-10-12 The Regents of the University of California Mutations in the BCR-abl tyrosine kinase associated with resistance to STI-571
WO2003000186A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
ES2255621T3 (en) 2001-06-22 2006-07-01 MERCK &amp; CO., INC. THYROSINE KINASE INHIBITORS.
DE60216281T2 (en) 2001-06-29 2007-07-05 Ab Science THE USE OF TYROSINE KINASE INHIBITOR FOR THE TREATMENT OF ALLERGIC DISEASES
WO2003004006A2 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
EP1401416B1 (en) 2001-06-29 2006-10-25 AB Science Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
CA2452169A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2452368A1 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
US20060204459A1 (en) * 2001-09-20 2006-09-14 Alain Moussy Use of tyrosine inhibitors for whitening human skin and treating melanocyted dysfunction associated diseases
WO2003040141A1 (en) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
EP2343366A1 (en) 2001-10-05 2011-07-13 Novartis AG Mutated Abl kinase domains
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
AU2007203462B2 (en) * 2002-02-07 2011-01-06 Novartis Pharma Ag N-phenyl-2-pyrimidine-amine derivatives
GB0202874D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
US20050153975A1 (en) * 2002-02-22 2005-07-14 Heinrich Michael C. Use of 4-(4-Methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating seminomas
DK1478380T3 (en) * 2002-02-27 2006-11-27 Ab Science Use of tyrosine kinase inhibitors to treat CNS disorders
ATE408407T1 (en) * 2002-02-27 2008-10-15 Ab Science USE OF TYROSINKINASE INHIBITORS TO TREAT SUBSTANCE USE-RELATED DISEASES
CN1326577C (en) * 2002-02-28 2007-07-18 诺瓦提斯公司 N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2003095448A1 (en) * 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
SI1505959T1 (en) 2002-05-16 2009-04-30 Novartis Ag Use of edg receptor binding agents in cancer
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004026930A2 (en) * 2002-06-26 2004-04-01 The Ohio State University Research Foundation The method for reducing inflammation using sti-571 or its salt
PT1533304E (en) * 2002-06-28 2010-02-08 Nippon Shinyaku Co Ltd Amide derivative
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
WO2004014903A1 (en) * 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
JP2006504721A (en) * 2002-10-11 2006-02-09 ノバルティス　アクチエンゲゼルシャフト Use of Imatinib (Gleevec, STI-571) to inhibit breast cancer resistance protein (BCRP) -mediated resistance to therapeutic agents
GB0224455D0 (en) * 2002-10-21 2002-11-27 Novartis Ag Organic compounds
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
EP1610838A1 (en) * 2003-04-04 2006-01-04 Bayco Tech Limited Vascular stent
WO2004099186A1 (en) 2003-05-06 2004-11-18 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
CL2004001120A1 (en) 2003-05-19 2005-04-15 Irm Llc COMPOUNDS DERIVED FROM AMINA REPLACED WITH HETEROCICLES, IMMUNOSUPPRESSORS; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT DISEASES MEDIATED BY LYMPHOCYTE INTERACTIONS, SUCH AS AUTOIMMUNE, INFLAMMATORY, INFECTIOUS, CANCER DISEASES.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
NZ543709A (en) * 2003-05-27 2009-04-30 Robert Per Hagerkvist Use of tyrosine kinase inhibitor to treat diabetes
CA2529090A1 (en) * 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors
CA2876822C (en) 2003-08-27 2015-11-17 David Shima Combination therapy for the treatment of ocular neovascular disorders
JP4762150B2 (en) 2003-11-18 2011-08-31 ノバルティス アーゲー KIT mutant inhibitors
KR100848067B1 (en) * 2003-12-25 2008-07-23 니뽄 신야쿠 가부시키가이샤 Amide derivative and medicine
EP1725295B1 (en) * 2004-01-21 2010-09-15 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
PE20051096A1 (en) 2004-02-04 2006-01-23 Novartis Ag SALT FORMS OF 4- (4-METHYLPIPERAZIN-1-ILMETHYL) -N- [4-METHYL-3- (4-PYRIDIN-3-IL) PYRIMIDIN-2-ILAMINO) PHENYL] -BENZAMIDE
PT1720853E (en) 2004-02-11 2016-03-04 Natco Pharma Ltd Novel polymorphic form of imatinib mesylate and a process for its preparation
CN1309719C (en) * 2004-02-18 2007-04-11 陈国庆 Derivative of phenylamide pyrimidine and application thereof
EP2065368A1 (en) 2004-04-07 2009-06-03 Novartis Ag Inhibitors of IAP
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1786781A2 (en) * 2004-08-27 2007-05-23 GPC Biotech AG Pyrimidine derivatives
US8269003B2 (en) 2004-09-02 2012-09-18 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
MX2007002819A (en) 2004-09-09 2007-08-14 Natco Pharma Ltd Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase.
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
SI1833815T1 (en) * 2004-12-30 2011-01-31 Inst Farmaceutyczny A process for preparation of imatinib base
CN1939910A (en) * 2004-12-31 2007-04-04 孙飘扬 Amino-metadiazine compound and its salt, its preparation and pharmaceutical use
CN1972917B (en) * 2004-12-31 2010-08-25 孙飘扬 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
BRPI0606480A (en) 2005-01-21 2008-03-11 Astex Therapeutics Ltd pharmaceutical compounds
AU2006242311B2 (en) 2005-05-02 2010-03-04 Novartis Ag Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
AU2006314444C1 (en) 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
CA2824301C (en) 2005-11-25 2016-01-12 Novartis Ag F, g, h, i and k crystal forms of imatinib mesylate
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
EP2606890A1 (en) 2006-04-05 2013-06-26 Novartis AG Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
BRPI0709750A2 (en) 2006-04-05 2011-07-26 Novartis Ag combinations of therapeutic agents for cancer treatment
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
JP2009536180A (en) 2006-05-09 2009-10-08 ノバルティス アクチエンゲゼルシャフト Combinations comprising iron chelators and antineoplastic agents and their use
US20060223817A1 (en) * 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
CA2651368A1 (en) 2006-06-01 2007-12-06 Japan As Represented By Director General Of Agency Of National Cancer Center Tumor suppressor
RU2009115954A (en) 2006-09-29 2010-11-10 Новартис АГ (CH) Pyrazolopyrimidines as P13K Lipid Kinase Inhibitors
JP5528807B2 (en) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド Compound drug
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP2009514988A (en) * 2006-10-26 2009-04-09 シコール インコーポレイティド Imatinib base and imatinib mesylate and methods for their preparation
WO2008059551A2 (en) 2006-11-16 2008-05-22 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the preparation of imatinib and intermediates thereof
CN101245061B (en) * 2007-02-13 2012-09-19 天津天士力集团有限公司 N-(5-amido-2-methyl phenyl)-4-(3-pyridinyl)-2-aminopyrimidine nitric oxide donating derivant, production method and uses thereof
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
RU2329260C1 (en) * 2007-02-20 2008-07-20 Юрий Иосифович Копырин Method of obtaining 2-anilinopyrimidines or their salts (options)
MX2009009659A (en) * 2007-03-12 2009-09-22 Reddys Lab Ltd Dr Imatinib mesylate.
WO2008117298A1 (en) * 2007-03-26 2008-10-02 Natco Pharma Limited A novel method of preparation of imatinib
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
US8367686B2 (en) 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
JP5559043B2 (en) 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド Novel heterocyclic compounds and uses thereof
WO2009032861A1 (en) * 2007-09-04 2009-03-12 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009060463A1 (en) * 2007-11-05 2009-05-14 Natco Pharma Limited An environmentally friendly process for the preparation of imatinib base
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
PT2252597E (en) * 2008-02-01 2014-04-30 Akinion Pharmaceuticals Ab Pyrazine derivatives and their use as protein kinase inhibitors
KR101673621B1 (en) 2008-03-24 2016-11-07 노파르티스 아게 Arylsulfonamide-based matrix metalloprotease inhibitors
BRPI0909159A2 (en) 2008-03-26 2015-11-24 Novartis Ag deacetylase b hydroxamate based inhibitors
CN101584696A (en) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 Composition containing quinazoline derivatives, preparation method and use
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EA029131B1 (en) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Phosphorous derivatives as kinase inhibitors
PL215042B1 (en) * 2008-08-01 2013-10-31 Temapharm Spolka Z Ograniczona Odpowiedzialnoscia Method of imatinib manufacturing
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
EP3626238A1 (en) 2008-08-15 2020-03-25 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
PL2350129T3 (en) 2008-08-25 2015-12-31 Amplimmune Inc Compositions of pd-1 antagonists and methods of use
US20110223241A1 (en) 2008-10-16 2011-09-15 Celator Pharmaceuticals, Inc. Combination methods and compositions
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
KR20110112352A (en) 2008-12-18 2011-10-12 노파르티스 아게 New polymorphic form of 1-(4-{l-[(e)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic
PT2379497E (en) 2008-12-18 2013-11-29 Novartis Ag Hemifumarate salt of 1- ã¿4- ã¿1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethylâ¿-2 -ethyl-benzylâ¿-a zetidine-3-carboxylic acid
CN103204794A (en) 2008-12-18 2013-07-17 诺瓦提斯公司 New Salts
CN102256976A (en) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 Salt forms of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
TWI466672B (en) 2009-01-29 2015-01-01 Boehringer Ingelheim Int Treatment for diabetes in paediatric patients
SI2391366T1 (en) 2009-01-29 2013-01-31 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
CA2752437C (en) 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
JP2012518657A (en) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー Combined anticancer treatment
JP2012519282A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
JP2012519281A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
UA105794C2 (en) 2009-06-26 2014-06-25 Новартіс Аг 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS Cyp17 INHIBITORS
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
BR112012008061A2 (en) 2009-08-20 2016-03-01 Novartis Ag heterocyclic oxime compounds
KR20120050492A (en) 2009-08-26 2012-05-18 노파르티스 아게 Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
US20120165310A1 (en) 2009-09-10 2012-06-28 Novartis Ag Ether derivatives of bicyclic heteroaryls
MX370429B (en) 2009-10-02 2019-12-13 Boehringer Ingelheim Int Gmbh Star Pharmaceutical compositions comprising bi-1356 and metformin.
US8575168B2 (en) 2009-10-09 2013-11-05 Irm Llc Compounds and compositions as modulators of GPR119 activity
PL389357A1 (en) 2009-10-22 2011-04-26 Tomasz Koźluk Tartaric acids derivatives imatinib salts and process for the preparation thereof
EA201200651A1 (en) 2009-11-04 2012-12-28 Новартис Аг HETEROCYCLIC SULPHONAMIDE DERIVATIVES APPLICABLE AS MEK INHIBITORS
US20110237540A1 (en) 2009-11-23 2011-09-29 Crawford Thomas C Cyclodextrin-based polymers for therapeutic delivery
CN102712648A (en) 2009-11-25 2012-10-03 诺瓦提斯公司 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
KR20210033559A (en) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
US8614239B2 (en) 2009-12-08 2013-12-24 Novartis Ag Heterocyclic sulfonamide derivatives
EP2509973A1 (en) 2009-12-10 2012-10-17 Arch Pharmalabs Limited Process for the preparation of imatinib and salts thereof
CU24130B1 (en) 2009-12-22 2015-09-29 Novartis Ag ISOQUINOLINONES AND REPLACED QUINAZOLINONES
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
AU2011213936A1 (en) 2010-02-15 2012-09-06 Sharma Ashwani Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (en) 2010-03-04 2011-09-12 Tomasz Koźluk Process for the preparation of polymorphic alpha form and new polymorphic form of imatinib mesylate
CA2792472A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
US8609842B2 (en) * 2010-04-23 2013-12-17 Fujian South Pharmaceutical Co., Ltd. Method for synthesizing Imatinib
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
CN102946875A (en) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 Combination therapy
JP2013532149A (en) 2010-06-17 2013-08-15 ノバルティス アーゲー Piperidinyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
CN102947274A (en) 2010-06-17 2013-02-27 诺瓦提斯公司 Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
SI2582689T1 (en) 2010-06-18 2017-05-31 Krka, D.D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
EP2582362A1 (en) 2010-06-21 2013-04-24 Zaklady Farmaceutyczne "Polpharma" S.A. Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
NZ605449A (en) 2010-07-09 2015-03-27 Genentech Inc Anti-neuropilin antibodies and methods of use
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
MX2013001653A (en) 2010-08-11 2013-05-22 Synthon Bv Pharmaceutical granulate comprising imatinib mesylate
TR201007005A2 (en) 2010-08-23 2011-09-21 Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. Imatinib base production method
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
TR201010618A2 (en) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut An oral dosage form comprising imatinib and the manufacture of an oral dosage form
WO2012085815A1 (en) 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
TWI592411B (en) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 Combination of kinase inhibitors and uses thereof
JP5808826B2 (en) 2011-02-23 2015-11-10 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
CZ305457B6 (en) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidine compounds inhibiting formation of nitrogen monoxide and prostaglandin E2, process for their preparation and use
CN103492390A (en) 2011-03-08 2014-01-01 诺瓦提斯公司 Fluorophenyl bicyclic heteroaryl compounds
PL394169A1 (en) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością The pharmaceutical composition of imatinib mesylate for filling unit dosage forms and the method for its preparation
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
ES2656218T3 (en) 2011-04-28 2018-02-26 Novartis Ag 17 alpha-hydroxylase / C17,20-lyase inhibitors
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN102796110B (en) * 2011-05-23 2016-03-30 复旦大学 Aniline pyrimidine compound and its production and use
BR112013031201A2 (en) 2011-06-09 2017-01-31 Novartis Ag heterocyclic sulfonamide derivatives, pharmaceutical composition comprising them, use, process for the manufacture of (r) -n- (4,5-difluoro-6 - ((2-fluoro-4-iodophenyl) amino) benzofuran-7-yl) -1- (2,3-dihydroxypropyl) cyclopropane-5-1-sulfonamide and kit
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
EP2721008B1 (en) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
US9750700B2 (en) 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
MX2013015001A (en) 2011-06-27 2014-03-31 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives.
ITMI20111309A1 (en) 2011-07-14 2013-01-15 Italiana Sint Spa PREPARATION PROCEDURE OF IMATINIB MESILATO
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013035102A1 (en) 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
JP6096205B2 (en) 2011-11-01 2017-03-15 モッドジーン リミテッド ライアビリティ カンパニーＭｏｄｇｅｎｅ，Ｌｌｃ Use of imatinib derivatives exhibiting reduced protein kinase inhibition
RU2486180C1 (en) * 2011-11-02 2013-06-27 Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") Method for preparing 2-arylamino-4-hetarylpyrimidines
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159739A (en) * 2011-12-09 2013-06-19 天津市国际生物医药联合研究院有限公司 1, 4-disubstituted-1, 2, 3-triazole compounds and preparation method thereof
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
PT2794600T (en) 2011-12-22 2018-03-13 Novartis Ag 2,3-dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (pi3k) inhibitors for the treatment of e.g. rheumatoid arthritis
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859867A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015442A8 (en) 2011-12-23 2017-07-04 Novartis Ag compounds and compositions for inhibiting bcl2 interaction with binding partners
JP2015503515A (en) 2011-12-23 2015-02-02 ノバルティス アーゲー COMPOUND AND COMPOSITION FOR INHIBITING BCL2 AND BINDING PARTY INTERACTION
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
PL226174B1 (en) 2011-12-30 2017-06-30 Inst Farm Combination therapy of non-small-cell lung carcinoma
UY34591A (en) 2012-01-26 2013-09-02 Novartis Ag IMIDAZOPIRROLIDINONA COMPOUNDS
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
WO2013136141A1 (en) 2012-03-13 2013-09-19 Fresenius Kabi Oncology Ltd. An improved process for the preparation of alpha form of imatinib mesylate
CN110507654A (en) 2012-04-03 2019-11-29 诺华有限公司 Combination with tyrosine kinase inhibitors and use thereof
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9567304B2 (en) 2012-04-24 2017-02-14 Chugai Seiyaku Kabushiki Kaisha Quinazolinedione derivative
CA2871237A1 (en) 2012-04-24 2013-10-31 Chugai Seiyaku Kabushiki Kaisha Benzamide derivative
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
JP6218811B2 (en) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Xanthine derivatives as DPP-4 inhibitors for use in the treatment of SIRS and / or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
BR112014031421A2 (en) 2012-06-15 2017-06-27 Brigham & Womens Hospital Inc cancer treatment compositions and methods for producing them
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
EP2879675B1 (en) 2012-08-06 2019-11-13 Duke University Compounds and methods for targeting hsp90
WO2014041551A1 (en) 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
CN103664787B (en) 2012-09-17 2015-09-09 南京圣和药业股份有限公司 Alkynes heteroaromatic ring compounds and application thereof
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
EP2902028A1 (en) 2012-09-28 2015-08-05 Hangzhou Bensheng Pharmaceutical Co., Ltd. Drug composition for treating tumors and application thereof
CA2886744A1 (en) * 2012-10-04 2014-04-10 Inhibikase Therapeutics, Inc. Imatinib derivatives, their preparation and use to treat cancer and bacterial and viral infections
AU2013337247B2 (en) 2012-11-05 2018-08-09 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
TW201422625A (en) 2012-11-26 2014-06-16 Novartis Ag Solid form of dihydro-pyrido-oxazine derivative
CN103848812B (en) * 2012-12-04 2016-08-03 北大方正集团有限公司 The method of refined imatinib
CN103044394A (en) * 2012-12-20 2013-04-17 北京理工大学 Phenyl aminopyrimidine derivant and preparation method and application thereof
EP2749271A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Optimized manufacturing method and pharmaceutical formulation of imatinib
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
US9394368B2 (en) 2013-02-20 2016-07-19 Novartis Ag Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
JP2016510795A (en) 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of linagliptin in cardioprotective and renal protective antidiabetic treatments
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc Combination of kinase inhibitors and uses thereof
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
SG11201600028YA (en) 2013-09-22 2016-02-26 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use
ES2748213T3 (en) 2013-10-17 2020-03-13 Sartar Therapeutics Ltd Compositions comprising phosphodiesterase inhibitors for use in treating a solid tumor in a human patient
TW201605805A (en) 2013-10-23 2016-02-16 Chugai Pharmaceutical Co Ltd Quinazolinone and isoquinolinone derivative
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
MX2016012574A (en) 2014-03-28 2017-09-26 Calitor Sciences Llc Substituted heteroaryl compounds and methods of use.
RU2016140160A (en) 2014-04-03 2018-05-07 Инвиктус Онколоджи Пвт. Лтд. SUPRAMOLECULAR COMBINATOR MEDICINES
EP2927223B1 (en) 2014-04-04 2016-06-29 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for preparing imatinib and salts thereof, free of genotoxic impurity f
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
CN105585556A (en) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 Synthetic method of imatinib
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
EP3240538B1 (en) 2016-03-25 2021-09-29 AB Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
CN107652269A (en) * 2016-07-26 2018-02-02 江苏豪森药业集团有限公司 Methanesulfonic acid fluorine imatinib purification of intermediate method
EP3503914A1 (en) 2016-08-23 2019-07-03 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
CN107805240A (en) * 2016-09-08 2018-03-16 中国科学院合肥物质科学研究院 A kind of new PDGFR kinase inhibitors and application thereof
KR20190054094A (en) 2016-09-27 2019-05-21 세로 테라퓨틱스, 인코포레이티드 Chimeric phagocytic receptor molecule
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
EP3333162A1 (en) 2016-12-12 2018-06-13 Silesian Catalysts sp. z o.o. Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
CN107089969B (en) * 2017-04-26 2020-04-24 黑龙江鑫创生物科技开发有限公司 Method for synthesizing imatinib intermediate
CN111386284B (en) 2017-09-26 2024-08-30 森罗治疗公司 Chimeric phagocytic receptor molecules and methods of use
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. Peptide vaccines and hdac inhibitors for treating multiple myeloma
AU2018353984A1 (en) 2017-10-24 2020-05-07 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
JP7021356B2 (en) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ Pyrimidine derivative kinase inhibitors
KR20200112900A (en) 2018-01-20 2020-10-05 선샤인 레이크 파르마 컴퍼니 리미티드 Substituted aminopyrimidine compounds and methods of use thereof
MX2020010235A (en) 2018-03-28 2020-10-28 Cero Therapeutics Inc Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof.
EP3774906A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
AU2019243154A1 (en) 2018-03-28 2020-10-01 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
US20210299129A1 (en) 2018-07-17 2021-09-30 Boehringer Ingelheim International Gmbh Cardiosafe Antidiabetic Therapy
EP3823625A1 (en) 2018-07-17 2021-05-26 Boehringer Ingelheim International GmbH Cardio- and renosafe antidiabetic therapy
WO2020023628A1 (en) 2018-07-24 2020-01-30 Hygia Pharmaceuticals, Llc Compounds, derivatives, and analogs for cancer
US20220265653A1 (en) 2019-07-15 2022-08-25 Intas Pharmaceuticals Ltd. Pharmaceutical composition of imatinib
WO2021067875A1 (en) 2019-10-03 2021-04-08 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
WO2022047259A1 (en) 2020-08-28 2022-03-03 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
KR20230160242A (en) 2021-02-26 2023-11-23 켈로니아 테라퓨틱스, 인코포레이티드 Lymphocyte-targeted lentiviral vectors
WO2023010097A1 (en) 2021-07-28 2023-02-02 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
WO2024030441A1 (en) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47583A1 (en) * 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines

Also Published As

Publication number Publication date
SK28093A3 (en) 1994-04-06
CN1043531C (en) 1999-06-02
PT564409E (en) 2000-06-30
MX9301929A (en) 1994-07-29
HUT64050A (en) 1993-11-29
SG43859A1 (en) 1997-11-14
DE10299016I2 (en) 2006-08-24
HU227080B1 (en) 2010-06-28
IL105264A (en) 1999-04-11
DE59309931D1 (en) 2000-02-24
SA93140441B1 (en) 2005-12-14
BR1100739A (en) 2000-06-06
RU2125992C1 (en) 1999-02-10
TW225528B (en) 1994-06-21
JP2706682B2 (en) 1998-01-28
FI931458A (en) 1993-10-04
EP0564409B1 (en) 2000-01-19
DK0564409T3 (en) 2000-06-19
NL300086I1 (en) 2002-05-01
KR930021624A (en) 1993-11-22
CZ56093A3 (en) 1994-02-16
CN1077713A (en) 1993-10-27
EP0564409A1 (en) 1993-10-06
FI931458A0 (en) 1993-03-31
HU226488B1 (en) 2009-03-02
NO931283D0 (en) 1993-04-02
CY2003003I1 (en) 2010-07-28
CA2093203C (en) 2002-11-26
CZ283944B6 (en) 1998-07-15
ATE188964T1 (en) 2000-02-15
CA2093203A1 (en) 1993-10-04
DE10299016I1 (en) 2002-08-29
LU90908I2 (en) 2003-04-30
NO302473B1 (en) 1998-03-09
CY2229B1 (en) 2003-04-18
SK280620B6 (en) 2000-05-16
FI109534B (en) 2002-08-30
NL300086I2 (en) 2002-06-03
ES2142857T3 (en) 2000-05-01
AU666709B2 (en) 1996-02-22
NO2002001I2 (en) 2007-01-29
GR3032927T3 (en) 2000-07-31
AU3569493A (en) 1993-10-07
KR100261366B1 (en) 2002-07-18
NZ247299A (en) 1995-07-26
JPH0687834A (en) 1994-03-29
IL105264A0 (en) 1993-08-18
HU9300982D0 (en) 1993-06-28
NO931283L (en) 1993-10-04

Similar Documents

Publication Publication Date Title
AU666709B2 (en) Pyrimidine derivatives and processes for the preparation thereof
RU93005357A (en) Pyrimidine derivatives and method of their manufacture
MY107756A (en) Piperazine derivatives.
TW358808B (en) Morpholine derivatives, preparation thereof and pharmaceutical composition containing the same
GB2248616B (en) Piperazine derivatives
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
NZ218243A (en) B-carboline derivatives and pharmaceutical compositions
IL80216A0 (en) 3-vinyl-and 3-ethinyl-beta-carboline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB9300195D0 (en) Piperazine derivatives
MY129935A (en) Dihydropyridine derivatives useful in antitumor therapy
BG101601A (en) Pharmaceutical piperazine compounds
DE69431471D1 (en) AMIDE DERIVATIVES AS 5-HT1A LIGANDS
TW330147B (en) Halogenobenzimidazoles, their preparation processes and their use
NZ291855A (en) Bridged azabicyclo-piperazin-1-yl-2-phenyl-butan-1-one derivatives as 5-ht1a antagonists
DE68914392D1 (en) Use of oxidized polyamides, especially NN&#39;-bis- (3-propionaldehyde) -1-4-diaminobutane, as immunosuppressants.
TW257758B (en) Piperazine derivatives (1)
GB1185524A (en) Quinazolinone Derivatives
TW356466B (en) Piperazine derivatives and pharmaceutical compositions containing the same for anti-cancer